Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent

• Published in: Ecancermedicalscience Vol. 9; p. 513
• Main Author: Van Nuffel, An MT
• Format: Journal Article
• Language: English
• Published: England Cancer Intelligence 24.02.2015
• Subjects: Conference Report; ReDO project; antineoplastic agents; clarithromycin; anti-bacterial agents; drug repositioning; neoplasms
• ISSN: 1754-6605; 1754-6605
• DOI: 10.3332/ecancer.2015.513

Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with Helicobacter pylori. Extensive preclinical and clinical data demonstrate a potential role for CAM to treat various tumours in combination with conventional treatment. The mechanisms of action underlying the anti-tumour activity of CAM are multiple and include prolonged reduction of pro-inflammatory cytokines, autophagy inhibition, and anti-angiogenesis. Here, we present an overview of the current preclinical (in vitro and in vivo) and clinical evidence supporting the role of CAM in cancer. Overall these findings justify further research with CAM in many tumour types, with multiple myeloma, lymphoma, chronic myeloid leukaemia (CML), and lung cancer having the highest level of evidence. Finally, a series of proposals are being made to further investigate the use of CAM in clinical trials which offer the greatest prospect of clinical benefit to patients.